Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.6%

7 terminated/withdrawn out of 45 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

52%

13 of 25 completed trials have results

Key Signals

4 recruiting13 with results7 terminated

Enrollment Performance

Analytics

N/A
17(53.1%)
Phase 2
8(25.0%)
Phase 1
4(12.5%)
Phase 4
2(6.3%)
Phase 3
1(3.1%)
32Total
N/A(17)
Phase 2(8)
Phase 1(4)
Phase 4(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials
NCT07501078Phase 2Not Yet Recruiting

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

Role: collaborator

NCT04974099Phase 2Terminated

Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

Role: collaborator

NCT04114292Phase 1Completed

TUDCA as a Therapy for Ulcerative Colitis (UC)

Role: collaborator

NCT05561738Not ApplicableRecruiting

Nicotinamide Riboside in Ulcerative Colitis

Role: collaborator

NCT03256240Not ApplicableRecruiting

Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

Role: collaborator

NCT02791854Enrolling By Invitation

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

Role: collaborator

NCT00904878Recruiting

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

Role: collaborator

NCT04186247Phase 2Terminated

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Role: collaborator

NCT03397108Completed

Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

Role: collaborator

NCT05119140Phase 1Active Not Recruiting

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Role: collaborator

NCT03998488Phase 2Completed

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

Role: collaborator

NCT05635292Not ApplicableCompleted

Addressing Disability Effectively With Psychosocial Telemedicine

Role: collaborator

NCT04852666Completed

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

Role: collaborator

NCT05230173Not ApplicableRecruiting

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Role: collaborator

NCT02765256Phase 2Completed

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Role: collaborator

NCT04897282Unknown

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

Role: collaborator

NCT05931458Not ApplicableNot Yet Recruiting

AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis

Role: collaborator

NCT05034159Not ApplicableCompleted

CBT-I for Sleep, Pain, and Inflammation in Crohn's Disease

Role: collaborator

NCT04655729Unknown

Biomarkers to Predict and Monitor Response to Infliximab

Role: collaborator

NCT05230160Not ApplicableUnknown

Can Intermittent Fasting Induce Weight Loss and Improve Gut Health as Compared to Standard Medical Care in Patients With Obesity/High BMI and Crohn's Disease.

Role: collaborator